Glufast On Insulin Glargine Trial in Type 2 DM

Inclusion Criteria: * The type 2 diabetic patients aged between 30 and 70 * The patients whose Hb1Ac is over 7.0% despite administration of two or more oral antidiabetic drugs over 6 months or only insulin glargine over 3 months before registration * Outpatients whose BMI is between 21 and 40 kg/㎡ * The patients who consented to participate in the clinical study in writing Exclusion Criteria: * The patients who have been using insulin formulation except insulin glargine * The patients whose fasting blood glucose is over 270 mg/dL * The patients whose C-peptide is under 1ng/ml on an empty stomach * The patients who was surgically operated of gastrointestinal tract * The patients who need additional treatment or who underwent operation within 3 months for severe complication such as diabetic foot ulcer, retinopathy and neuropathy * The patients with severe hepatic dysfunction : uncompensated hepatic cirrhosis, or the case where aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is over 2.5 times higher than the normal limit ( ≥ 2.5 x normal ranges) * The patients with unstable angina or acute myocardial infarction occurred within 3months * The patients with renal failure or severe hypertension : diastolic blood pressure is over 110mmHg despite drug treatment * The patients who have a life-threatening disease such as cancer or severe infection * The patients with a history of drug allergy * Pregnant or breast feeding or the women who are likely to be pregnant * The patients who need oral or parenteral corticosteroids * The patients who were judged to be unsuitable to the clinical study by other reasons